Early Discontinuation of Ethambutol in Pulmonary Tuberculosis Treatment Based on Results of the GenoType MTBDRplus Assay: a Prospective, Multicenter, Noninferiority Randomized Trial in South Korea

No studies have investigated whether the discontinuation of ethambutol (EMB) based on susceptibility to isoniazid and rifampin, as determined by the GenoType MTBDRplus assay, would be appropriate. We aimed to determine the feasibility of discontinuing EMB before the end of the intensive phase of tre...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Antimicrob Agents Chemother
Auteurs principaux: Jo, Kyung-Wook, Kim, Mihye, Kim, Ye-Jee, Lee, Hyun-Kyung, Kim, Hyun Kuk, Jeon, Doosoo, Lyu, Jiwon, Park, Hye Kyeong, Mok, Jeongha, Kim, Ju Sang, Heo, Eun Young, Choi, Sang Bong, Yim, Jae-Joon, Shim, Tae Sun
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2019
Sujets:
Clinical Therapeutics
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6879208/
https://ncbi.nlm.nih.gov/pubmed/31527020
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00980-19
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires